COVID-19: Taiwan’s epidemiological characteristics and public and hospital responses

Chih-Ming Chang 1,2, Ting-Wan Tan 1, Tai-Cheng Ho 1, Chung-Chu Chen 3,4, Tsung-Hsien Su 4,5, Chien-Yu Lin 4,6

1 Department of Nursing, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan
2 Graduate Institute of Health Industry Management, Yuanpei University, Hsinchu, Taiwan
3 Department of Internal Medicine, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan
4 Department of Medicine, MacKay Medical College, New Taipei, Taiwan
5 Department of Obstetrics and Gynecology, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan
6 Department of Pediatrics, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan

Corresponding Author: Chien-Yu Lin
Email address: mmhped.lin@gmail.com

Background: Coronavirus disease 19 (COVID-19) is a global health threat with significant medical, economic, social, and political implications. The optimal strategies for combating COVID-19 have not been fully determined and vary across countries.

Methods: By the end of February 2020 in Taiwan, 2,150 patients received diagnostic COVID-19 testing and 39 confirmed cases were detected. This is a relatively lower rate of infection compared to other Asian countries. In this article, we summarize the epidemiological characteristics of the 39 infected patients as well as public and hospital responses to COVID-19.

Results: Thirty-nine COVID-19 cases and one death have been confirmed in Taiwan. Seventeen of these patients were infected by family members or in hospital wards, emphasizing how COVID-19 is mostly spread by close contact. We examined how hospital have responded to COVID-19, including their implementation of patient route control, outdoor clinics, hospital visit restrictions, and ward and staff modifications. We also studied the public’s use of face masks in response to COVID-19. These strategies may reduce the spread of COVID-19 in other countries.

Conclusion: The emergence and spread of COVID-19 is a threat to health worldwide. Taiwan has reported lower infected cases and its strategies may contribute to further disease prevention and control.
COVID-19: Taiwan’s epidemiological characteristics and public and hospital responses

Chih-Ming Chang¹, Ting-Wan Tan¹, Tai-Cheng Ho¹, Chung-Chu Chen²,³, Tsung-Hsien Su³,⁴, Chien-Yu Lin³,⁵

¹Department of Nursing, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan
²Department of Internal Medicine, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan
³Department of Medicine, MacKay Medical College, New Taipei, Taiwan
⁴Department of Obstetrics and Gynecology, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan
⁵Department of Pediatrics, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan

Corresponding Author:
Chien-Yu Lin
Hsinchu City, Taiwan
Email address: mmhpedit.linh@gmail.com
**Abstract**

**Background:**

Coronavirus disease 19 (COVID-19) is a global health threat with significant medical, economic, social, and political implications. The optimal strategies for combating COVID-19 have not been fully determined and vary across countries.

**Methods:**

By the end of February 2020 in Taiwan, 2,150 patients received diagnostic COVID-19 testing and 39 confirmed cases were detected. This is a relatively lower rate of infection compared to other Asian countries. In this article, we summarize the epidemiological characteristics of the 39 infected patients as well as public and hospital responses to COVID-19.

**Results:**

Thirty-nine COVID-19 cases and one death have been confirmed in Taiwan. Seventeen of these patients were infected by family members or in hospital wards, emphasizing how COVID-19 is mostly spread by close contact. We examined how hospital have responded to COVID-19, including their implementation of patient route control, outdoor clinics, hospital visit restrictions,-and ward and staff modifications. We also studied the public’s use of face masks in response to COVID-19. These strategies may reduce the spread of COVID-19 in other countries.

**Conclusion:**
The emergence and spread of COVID-19 is a threat to health worldwide. Taiwan has reported lower infected cases and its strategies may contribute to further disease prevention and control.
Introduction

The novel coronavirus, 2019-nCoV, emerged in Wuhan, China in December 2019 and has rapidly spread across the world (Gates 2020; Zhu et al. 2020). In February 2020, the World Health Organization (WHO) renamed this epidemic disease coronavirus disease (COVID-19) as it is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The number of COVID-19 cases has rapidly increased worldwide ((WHO) 2020; del Rio & Malani 2020). As of 29 February 2020, there were 85,403 confirmed COVID-19 cases and 2,924 fatalities across 49 countries ((WHO) 2020; Dong et al.). Although the emerging threat of COVID-19 has drawn global attention, the optimal strategies to reduce the spread of disease remain largely undetermined (Day 2020).

Several studies have investigated the virology, transmission, risk factors, and protection associated with COVID-19 (Chen et al.; Guan et al. 2020; Huang et al. 2020; Wang et al. 2020b; Wu & McGoogan 2020; Yang et al.). COVID-19 spreads by human-to-human transmission, primarily through respiratory droplets and direct contact with groups of infected family members, friends, colleagues, or medical health workers. However, even asymptomatic patients can be a source of infection. COVID-19 has dramatically higher rates of transmission compared to severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), but an observed lower fatality rate. The median age of COVID-19 patients ranged from 47 to 56 years old; approximately 65% of patients were male and 35% were female. Approximately 23.7% of adult COVID-19 patients have at least one of the following coexisting underlying chronic illnesses: cardiovascular disease, diabetes mellitus, hypertension, or chronic
obstructive lung disease. The most common reported symptoms are fever (43.8% on admission and 88.7% during hospitalization), dry cough (67.8%), dyspnea (18.7%), myalgia (14.9%), headache (13.6%), diarrhea (3.8%), sore throat (13.9%), nasal obstruction (4.8%), and fatigue (38.1%). The optimal infectious control measurements for COVID-19 have not yet been established (Razai et al. 2020).

COVID-19 is continuing to dramatically spread across many countries (WHO 2020). However, Taiwan has a relatively lower rate of infected cases. After the first diagnosed case in Taiwan on 21 January 2020, 39 cases were confirmed as of 29 February 2020. Some cases were imported by travelers and others were within families. We conducted this study to summarize the epidemiological characteristics of the 39 cases and to propose technological advances and infectious control measurements that may contribute to reducing disease spread (Chen et al., Wang et al. 2020a). We also discuss some of the Taiwanese public health’s and hospital’s responses to COVID-19.

Materials & Methods

1. Study design and data sources

We conducted this retrospective observational study at the end of February 2020 to investigate the epidemiological characteristics of the first 39 confirmed COVID-19 cases in Taiwan. The Taiwan Centers for Disease
Control (TCDC) enforced many policies to combat the spread of COVID-19 (Centers for Disease Control 2020). The epidemiological data of the confirmed cases were released to the public. Although the identifiable data were encrypted, the clinical presentations and epidemiological relationships were reported, and data regarding demographics, clinical symptoms, contact history, and onset dates were extracted. We summarized the public data to show the clinical characteristics of the 39 cases.

2. COVID-19 diagnoses

Since COVID-19 is considered a communicable disease in Taiwan, all suspected cases are required to be reported to the TCDC. The clinical COVID-19 diagnostic criteria include a history of travel or residence in endemic areas, contact with confirmed cases, contact with cases of fever or respiratory symptoms, radiological image characteristics of pneumonia, and clinical manifestations of fever or respiratory tract symptoms. Early diagnosis and timely containment are important. The TCDC’s diagnostic testing criterion included: (1) patients from endemic areas with respiratory symptoms; (2) patients with unexplained pneumonia or community pneumonia and poor responses to antibiotic treatment; (3) patients in close contact with confirmed cases; and (4) cluster infections or unwell people in specific workplaces, such as hospitals or nurseries. The defined endemic areas varied over time.

Suspected cases were confirmed by nucleic acid detection from the sputum, throat swab, lower respiratory tract secretion, or blood samples. The polymerase chain reaction for COVID-19 and other viruses were performed (Cui et al. 2019; Lin et al. 2020; Lu et al. 2020b; The 2020). The suspected
cases were isolated in negative pressure rooms or single bedrooms until a second negative test result.

3. COVID-19 treatment

Since there is no specific treatment for COVID-19, the main treatments used are supportive care and oxygen support (WHO 2020; Centers for Disease Control 2020). Suspected or confirmed cases were moved to isolated rooms and received supportive treatment to ensure electrolyte balance, closely monitored vital signs, and oxygen saturation. Routine blood tests and arterial blood gas analyses were administered if necessary. Chest imaging and other procedures were arranged. Patients with pneumonia received intravenous broad-spectrum antibiotics such as penicillin or ceftriaxone, and oseltamivir was also administered empirically. For confirmed cases, they could leave isolation and return home after three consecutive negative PCR tests. In average, it took approximately one month to achieve the criteria of de-isolation thus the capacity of isolated rooms was an important issue.

4. Public health and hospital responses

Widespread anxiety is anticipated when facing a novel and unknown infection (The 2020). The TCDC executed several policies, but individual hospitals were authorized to implement their own infective control measurements against COVID-19 in addition to their normal practices. For example, decreasing exposure was important to reduce disease spread, and hospitalized patients are susceptible to various kinds of infectious diseases including COVID-19. To reduce viral transmission, hospitals set up outdoor
clinics to care for patients with travel or contact histories. We investigated other important health policies and hospital responses.

**Results**

1. Epidemiological characteristics of confirmed cases

We summarized cumulative cases from other Asian countries starting in mid-February (Figure 1). By the end of February 2020, 2,150 patients in Taiwan had been tested for COVID-19. Among them, 39 (1.8%) patients tested positive for SARS-CoV-2. The epidemiological characteristics of the 39 confirmed cases are summarized in Table 1. Sixteen (41.0%) patients were male and 23 (59.0%) were female. Approximately half (53.8%) of these patients were between 41 and 60 years old. Nineteen cases (48.7%) had a history of overseas travel or residence or had visited China. Fifteen (38.5%) of the confirmed cases had direct contact transmission from infected family members. One patient (2.6%) died. The TCDC aggressively tracked the travel, occupation, contact, and cluster histories of the confirmed cases. The correlations among the 39 cases were plotted and publicly released (Figure 2).

2. Public health and hospital responses to COVID-19

2.1. Home quarantine and patient route control

Hospitals designated separate entrances and exits for patients and the public to prevent hospital-acquired COVID-19 infections. Suspected cases were treated separately from the emergency and outpatient cases throughout the duration of their hospital stay. When scheduling appointments online, the Tracking and Management Mechanism for People under Infection
Risk announcement appeared (Figure 3). If patients had any history of travel to endemic areas or of respiratory infection, they were guided to a special COVID-19 outdoor clinic (Figure 4).

Suspected cases were guided to an outdoor triage and then admitted to an isolation room. Diagnostic tests were performed in negative pressure rooms or single bedrooms. Hand sanitizer, masks, and COVID-19-related posters were posted at the hospital entrances. Patients and visitors had to wash their hands with alcohol hand gel before entering the hospital. These infectious control measurements all contributed to reducing hospital-acquired infections.

2.2. Hospital visit restrictions

Hospital visits are common in Asian cultures, so hospitals in Taiwan restricted visits to prevent COVID-19 infections and outbreaks. Instead of face-to-face hospital visits, video calls were recommended for family and friends to contact patients. Ward entrances were controlled by electromagnetic doors requiring access cards. Patients were not allowed in restricted areas. No more than two visitors were allowed to visit the same patient at the same time. Visitors with recent travel histories were restricted from entering the hospital (Figure 5). In the case of a confirmed infection, visitor registration provided clues for tracking the infectious source and their contacts.

2.3. Regulation of masks and other personal protective equipment

Surgical masks are basic protections that prevent human-to-human transmission of COVID-19. Taiwanese people tend to wear masks in large and crowded gathering areas in their daily lives to protect themselves and
others. In order to prevent public over-purchase and hoarding, the Taiwanese government took actions to recruit the mask factories and allocate all masks. The government helped factories upgrade their facilities, and mask production increased from 1 million per day in early February to 10 million per day in late February. The Taiwanese government issued surgical masks to all local hospitals and clinics to prevent shortages. Each medical staff member received one to two masks every day for regular use, and additional masks or N95 masks were provided for healthcare providers taking care of COVID-19 patients or performing invasive procedures. Moreover, the government provided surgical masks for susceptible populations, such as patients with cancer, hemodialysis, or those undergoing chemotherapy and radiotherapy. Upon hospital admission, one mask was given to patients with reduced nosocomial infection or hospital-acquired infection. To reduce community transmission, the government also issued surgical masks to children. Taiwanese residents needed to present a national health insurance card to purchase surgical masks from local pharmacies and primary healthcare units. This policy allowed each residence to purchase two masks weekly and prohibited repeat purchases.

2.4. Ward and staff modifications

Suspected and confirmed cases were admitted to their own rooms to ensure isolation. In order to minimize infections of healthcare providers, nursing staff adhered to group scheduling and fixed shifting, separated by meal breaks. Job and ward rotations were prohibited to reduce the chances of hospital-acquired transmission.
Discussion

COVID-19 is a global health threat, but Taiwan has a relatively lower rate of infection compared to other countries. Approximately 50% of Taiwan’s 39 confirmed cases were imported and 38.5% were infected by their own families. Aggressive tracking and epidemiological surveillance strategies contributed to identifying infectious sources and reducing disease spread. Furthermore, infectious control measurements in hospitals may have reduced the transmission of COVID-19.

There are no established best strategies against COVID-19 and policies differ across populations, geographic regions, cultures, countries, and time. “Lockdown” was a powerful strategy used by China to isolate infected people and reduce transmission, but it is not easily replicated in many countries. The United Kingdom’s “herd immunity” strategy also caught our attention (YONG 2020). However, Taiwan’s close proximity to and frequent interactions with China suggest that following the UK’s strategy could result in the collapse of the medical system. Moreover, convenience in travelling contributed to virus transmission thus disease spread was almost inevitable. The rapid spread of COVID-19 had been observed in UK and the “herd immunity” strategy had been abandoned. The UK government made efforts towards “containment” to slow down the virus transmission (Boyle 2020). We were still exploring the appropriate strategies to tackle COVID-19 in different situations.

Aggressive control measurements in Taiwan helped flatten the infectious curve, prevent medical collapse, and reduce case fatality rates. For example, there were 1,300 isolation rooms with an occupancy rate of approximately
70% in February 2020 (Centers for Disease Control 2020). Adequate isolation rooms ensured adequate containment and reduced the risk of community infections. Furthermore, wearing masks is already prevalent in Taiwanese society, and masks provide simple and direct protection against droplet infection (Leung et al. 2020). Wearing masks has not been a common practice in other countries (Desai & Mehrotra 2020). Taiwan’s aggressive strategies ensured the provision of adequate masks, decreasing both anxiety among the public and disease spread.

Although, the culture and population density of Japan are relatively similar to Taiwan’s, Japan’s situation was more complicated. They faced the complex issues with the Diamond Princess cruise ship carrying infected patients, quarantined in the port of Yokohama, Japan, and the Olympics, and they used different strategies to combat COVID-19 (Gallego et al. 2020; Montanari 2020). Optimal strategies varied across different countries and changed over time.

The COVID-19 pandemic is a rapidly changing situation. According to a study by the Chinese CDC, the majority of infected people are aged 30 to 79 years (87%). In Taiwan’s 39 confirmed cases, 35 (90%) were aged 30-79 years. Taiwan’s case fatality rate (1/39, 2.56%) was similar to China’s (1023/44672, 2.3%) (Wu & McGoogan 2020). Approximately half of Taiwanese patients (19/39, 48.7%) had an overseas travel history, but the high risk of community infection should not be ignored. Family and ward clusters are important transmission sources, and 22 people across five families were identified in the 39 reported cases. The high contagiousness of SARS-CoV-2 makes disease prevention difficult. Moreover, 81% of infected patients reported mild symptoms which were easily overlooked
leading to delayed diagnoses (Bai et al. 2020; Rothe et al. 2020). Aggressive tracking and infectious source identification lead to early quarantine, transmission prevention, and early diagnoses of patients with mild symptoms.

Although SARS-CoV-2’s complete route of transmission has not been completely identified, it is mainly spread via droplets and physical contact (Li et al. 2020; Lu et al. 2020a; Xu et al. 2020). Wearing masks and washing hands are essential and effective in preventing the spread of infectious disease (Leung et al.; MacIntyre & Chughtai 2015). Public panic is expected when an emerging disease appears likely to become endemic or a widespread epidemic (Bao et al. 2020; Medley & Vassall 2017), leading to a shortage of masks and increased risk of disease transmission. The TCDC’s mask policy is an executable and effective strategy to combat disease. Furthermore, hospitals implementing visitation restrictions and outdoor clinics may also reduce the risk of COVID-19 transmission.

Technological advances also contribute to improvements in infection control. Big data analytics, new technology, and proactive testing have been applied in the war against COVID-19 (Wang et al. 2020a). A real-time, interactive internet dashboard has also been utilized to provide timely information for the general public and healthcare providers (Dong et al.). These strategies are believed to be beneficial in preventing and controlling disease spread. We summarized some additional hospital responses and provided photographs for healthcare providers’ reference (Figures 1, 3, 4, 5).
Our study had some limitations. First, COVID-19 is a communicable disease and universal screening is not currently available. The number of patients with mild symptoms may be underestimated. Second, since SARS-CoV-2’s virology, transmission, incubation period, and contagious period are not fully understood, the most effective strategies to use against COVID-19 remain speculative. More studies are required to investigate the effectiveness of individual infectious control measurements.

Conclusions

The emergence of COVID-19 is a critical global issue. Taiwan’s 39 confirmed cases showed a similar age distribution as previous studies (Guan et al., 2020). The role of family and ward clusters in disease transmission was emphasized. Public health and hospitals’ patient route control, outdoor clinics, hospital visit restrictions, mask regulations, and ward and staff modification strategies may contribute to reducing the transmission of COVID-19.

Acknowledgements

We thank the Centers for Disease Control, Taiwan and all efforts to combat COVID-19. We thank David Singleton for his brilliant review and constructive comments. The quality of our manuscript has been improved following his precious suggestions.

References
(WHO) WHO. 2020. Novel coronavirus (2019-nCoV). Situation report. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed 14 March 2020).

Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, and Wang M. 2020. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 10.1001/jama.2020.2565

Bao Y, Sun Y, Meng S, Shi J, and Lu L. 2020. 2019-nCoV epidemic: address mental health care to empower society. The Lancet. 395:437-438. 10.1016/S0140-6736(20)30309-3

Boyle C. 2020. On coronavirus containment, Britain’s Johnson is less restrictive than other European leaders. Available at https://www.latimes.com/world-nation/story/2020-03-19/british-prime-minister-boris-johnsons-coronavirus-european-leaders (accessed 05 May 2020).

Centers for Disease Control T. 2020. Coronavirus disease-19. Available at https://www.cdc.gov.tw/En (accessed 14 March 2020).

Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q, Liao J, Yang H, Hou W, and Zhang Y. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet. 10.1016/S0140-6736(20)30360-3

Chen X, Tian J, Li G, and Li G. Initiation of a new infection control system for the COVID-19 outbreak. The Lancet Infectious Diseases. 10.1016/S1473-3099(20)30110-9

Cui J, Li F, and Shi ZL. 2019. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17:181-192. 10.1038/s41579-018-0118-9

Day M. 2020. Covid-19: surge in cases in Italy and South Korea makes pandemic look more likely. BMJ 368:m751. 10.1136/bmj.m751

del Rio C, and Malani PN. 2020. COVID-19—New Insights on a Rapidly Changing Epidemic. JAMA. 10.1001/jama.2020.3072

Desai AN, and Mehrotra P. 2020. Medical Masks. JAMA. 10.1001/jama.2020.2331

Dong E, Du H, and Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases. 10.1016/S1473-3099(20)30120-1

Gallego V, Nishiura H, Sah R, and Rodriguez-Morales AJ. 2020. The COVID-19 outbreak and implications for the Tokyo 2020 Summer Olympic Games. Travel Med Infect Dis. 101604. 10.1016/j.tmaid.2020.101604

Gates B. 2020. Responding to Covid-19 — A Once-in-a-Century Pandemic? New England Journal of Medicine. 10.1056/NEJMp2003762

Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, Liu L, Shan H, Lei C-I, Hui DSC, Du B, Li L-j, Zeng G, Yuen K-Y, Chan R-c, Tang C-I, Wang T, Chen P-y, Xiang J, Li S-y, Wang J-l, Liang Z-j, Peng Y-x, Wei L, Liu Y, Hu Y-h, Peng P, Wang J-m, Liu J-y, Chen Z, Li G, Zheng Z-j, Qiu S-q, Luo J, Ye C-j, Zhu S-y, and Zhong N-s. 2020. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 10.1056/NEJMoa2002032

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, and Cao B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 395:497-506. 10.1016/S0140-6736(20)30183-5

Leung CC, Lam TH, and Cheng KK. Mass masking in the COVID-19 epidemic: people need guidance. The Lancet. 10.1016/S0140-6736(20)30520-1

Leung NHL, Chu DKW, Shiu EYC, Chan K-H, McDevitt JJ, Hau BJP, Yen H-L, Li Y, Ip DKM, Peiris JSM, Seto W-H, Leung GM, Milton DK, and Cowling BJ. 2020. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nature Medicine. 10.1038/s41591-020-0843-2
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, and Feng Z. 2020. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. New England Journal of Medicine.

Lin C-Y, Hwang D, Chiu N-C, Weng L-C, Liu H-F, Mu J-J, Liu C-P, and Chi H. 2020. Increased Detection of Viruses in Children with Respiratory Tract Infection Using PCR. International Journal of Environmental Research and Public Health 17:564.

Lu C-w, Liu X-f, and Jia Z-f. 2020a. 2019-nCoV transmission through the ocular surface must not be ignored. The Lancet 395:e39. 10.1016/S0140-6736(20)30313-5

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, and Tan W. 2020b. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet 395:565-574. 10.1016/S0140-6736(20)30251-8

MacIntyre CR, and Chughtai AA. 2015. Facemasks for the prevention of infection in healthcare and community settings. BMJ : British Medical Journal 350:h694. 10.1136/bmj.h694

Medley GF, and Vassall A. 2017. When an emerging disease becomes endemic. Science 357:156-158. 10.1126/science.aam8333

Montanari S. 2020. Japan has a remarkably low number of coronavirus cases that experts worry may lead to a 'false sense of security'. Available at https://www.businessinsider.com/why-japan-cases-of-coronavirus-are-so-low-2020-3 (accessed 03/20 2020).

Razai MS, Doerholt K, Ladhani S, and Oakeshott P. 2020. Coronavirus disease 2019 (covid-19): a guide for UK GPs. BMJ 368:m800. 10.1136/bmj.m800

Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, Seilmaier M, Drosten C, Vollmar P, Zirglmaier K, Zange S, Wölfel R, and Hoelscher M. 2020. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. New England Journal of Medicine.

The L. 2020. COVID-19: fighting panic with information. The Lancet 395:537. 10.1016/S0140-6736(20)30379-2

Wang CJ, Ng CY, and Brook RH. 2020a. Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing. JAMA. 10.1001/jama.2020.3151

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, and Peng Z. 2020b. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 10.1001/jama.2020.1585

Wu Z, and McGoogan JM. 2020. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 10.1001/jama.2020.2648

Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, Li S-B, Wang H-Y, Zhang S, Gao H-N, Sheng J-F, Cai H-L, Qiu Y-Q, and Li L-J. 2020. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 368:m606. 10.1136/bmj.m606

Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, and Shang Y. Clinical course and outcomes of critically ill patients with
SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine*. 10.1016/S2213-2600(20)30079-5

YONG E. 2020. The U.K.'s Coronavirus ‘Herd Immunity’ Debacle. *Available at https://www.theatlantic.com/health/archive/2020/03/coronavirus-pandemic-herd-immunity-uk-boris-johnson/608065/* (accessed 2020/03/16).

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, and Tan W. 2020. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *New England Journal of Medicine* 382:727-733. 10.1056/NEJMoA2001017
Figure 1

- First case in Taiwan: 01/21
- First local case in Taiwan: 01/28
- First local family cluster in Taiwan: 02/16
- First case with unknown infectious source: 02/19

- Outpatient clinics: 01/22
- Mask rationing plan: 02/06
- Communicable disease: 01/15
- Retrieve mask factories: 01/31
- Ward and staff modifications: 02/26
- Restriction of hospital visits: 03/09

Patient number vs. Date (21-Jan to 10-Mar)
Figure 2
*Adopted and modified by Taiwan Centers for Disease Control.
Publication under the terms and conditions of the Creative Commons Attribution (CC BY) license
*Dotted lines: family cluster or ward cluster; pink color: imported cases; blue color: local infection; green star: out of quarantine; black arrow: route of transmission
In order to combat COVID-19, hospital visit is prohibited. If you have to enter hospital for medical aid, please WEAR MASK and WASH HANDS. Thank you.

If your family or you had abroad travel history, please go to Outdoor Clinics for help or make a phone call to change your appointment.
Figure 4
A shorter version of visitor restriction was posted to provide clear instructions to patients and visitors. If visitors were allowed to enter hospital, registration with detailed information was required for further contact tracing.
| Table 1 (on next page) |
| Clinical characteristics     | No. | Percentage (%) |
|------------------------------|-----|----------------|
| Total                        | 39  | 100            |
| Gender                       |     |                |
| male                         | 21  | 53.8           |
| female                       | 18  | 46.2           |
| Age (years old)              |     |                |
| 11～20                        | 2   | 5.1            |
| 21～30                        | 4   | 10.3           |
| 31～40                        | 4   | 10.3           |
| 41～50                        | 10  | 25.6           |
| 51～60                        | 11  | 28.2           |
| 61～70                        | 3   | 7.7            |
| 71～80                        | 3   | 7.7            |
| >81                          | 2   | 5.1            |
| Travel history               |     |                |
| none                         | 20  | 51.3           |
| yes                          | 19  | 48.7           |
| Family cluster infection     |     |                |
| none                         | 21  | 53.8           |
| yes                          | 17  | 43.6           |
| unknown source               | 1   | 2.6            |